Adrian Mor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adrian Mor has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Dariusz Pawlak
Department of Pharmacodynamics, Medical University of Bialystok, 15-222 Bialystok, Poland
6 shared publications Bartlomiej Kalaska
Medical University of Bialystok, Pharmacodynamics, Bialystok, Poland
3 shared publicationsKrystyna Pawlak
Medical University of Bialystok, Monitored Pharmacotherapy, Bialystok, Poland
3 shared publications- Anna Tankiewicz-Kwedlo
Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland
2 shared publications Beata Sieklucka
Medical University of Bialystok, Pharmacodynamics, Bialystok, Poland
2 shared publicationsDariusz Pawlak
Medical University of Bialystok, Pharmacodynamics, Bialystok, Poland
2 shared publications
Latest Publications
- Open Access
Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders
This review discusses the potential of targeting the kynurenine pathway (KP) in the treatment of inflammatory diseases. The KP, responsible for the catabolism of the amino acid tryptophan (TRP), produces metabolites that regulate various physiological processes, including inflammation, cell cycle, and neurotransmission. These metabolites, although necessary to maintain immune balance, may accumulate excessively during inflammation, leading to systemic disorders. Key KP enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), tryptophan 2,3-dioxygenase (TDO), and kynurenine 3-monooxygenase (KMO) have been considered promising therapeutic targets. It was highlighted that both inhibition and activation of these enzymes may be beneficial, depending on the specific inflammatory disorder. Several inflammatory conditions, including autoimmune diseases, for which modulation of KP activity holds therapeutic promise, have been described in detail. Preclinical studies suggest that this modulation may be an effective treatment strategy for diseases for which treatment options are currently limited. Taken together, this review highlights the importance of further research on the clinical application of KP enzyme modulation in the development of new therapeutic strategies for inflammatory diseases.
Open AccessKynurenines as a Novel Target for the Treatment of Inflammatory Disorders
This review discusses the potential of targeting the kynurenine pathway (KP) in the treatment of inflammatory diseases. The KP, responsible for the catabolism of the amino acid tryptophan (TRP), produces metabolites that regulate various physiological processes, including inflammation, cell cycle, and neurotransmission. These metabolites, although necessary to maintain immune balance, may accumulate excessively during inflammation, leading to systemic disorders. Key KP enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), tryptophan 2,3-dioxygenase (TDO), and kynurenine 3-monooxygenase (KMO) have been considered promising therapeutic targets. It was highlighted that both inhibition and activation of these enzymes may be beneficial, depending on the specific inflammatory disorder. Several inflammatory conditions, including autoimmune diseases, for which modulation of KP activity holds therapeutic promise, have been described in detail. Preclinical studies suggest that this modulation may be an effective treatment strategy for diseases for which treatment options are currently limited. Taken together, this review highlights the importance of further research on the clinical application of KP enzyme modulation in the development of new therapeutic strategies for inflammatory diseases.
- Open Access
Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders
Neurodegenerative disorders are chronic and life-threatening conditions negatively affecting the quality of patients’ lives. They often have a genetic background, but oxidative stress and mitochondrial damage seem to be at least partly responsible for their development. Recent reports indicate that the activation of the kynurenine pathway (KP), caused by an activation of proinflammatory factors accompanying neurodegenerative processes, leads to the accumulation of its neuroactive and pro-oxidative metabolites. This leads to an increase in the oxidative stress level, which increases mitochondrial damage, and disrupts the cellular energy metabolism. This significantly reduces viability and impairs the proper functioning of central nervous system cells and may aggravate symptoms of many psychiatric and neurodegenerative disorders. This suggests that the modulation of KP activity could be effective in alleviating these symptoms. Numerous reports indicate that tryptophan supplementation, inhibition of KP enzymes, and administration or analogs of KP metabolites show promising results in the management of neurodegenerative disorders in animal models. This review gathers and systematizes the knowledge concerning the role of metabolites and enzymes of the KP in the development of oxidative damage within brain cells during neurodegenerative disorders and potential strategies that could reduce the severity of this process.
Open AccessRole of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders
Neurodegenerative disorders are chronic and life-threatening conditions negatively affecting the quality of patients’ lives. They often have a genetic background, but oxidative stress and mitochondrial damage seem to be at least partly responsible for their development. Recent reports indicate that the activation of the kynurenine pathway (KP), caused by an activation of proinflammatory factors accompanying neurodegenerative processes, leads to the accumulation of its neuroactive and pro-oxidative metabolites. This leads to an increase in the oxidative stress level, which increases mitochondrial damage, and disrupts the cellular energy metabolism. This significantly reduces viability and impairs the proper functioning of central nervous system cells and may aggravate symptoms of many psychiatric and neurodegenerative disorders. This suggests that the modulation of KP activity could be effective in alleviating these symptoms. Numerous reports indicate that tryptophan supplementation, inhibition of KP enzymes, and administration or analogs of KP metabolites show promising results in the management of neurodegenerative disorders in animal models. This review gathers and systematizes the knowledge concerning the role of metabolites and enzymes of the KP in the development of oxidative damage within brain cells during neurodegenerative disorders and potential strategies that could reduce the severity of this process.
- Open Access
- 23 June 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 606
Kynurenines as a Novel Target for the Treatment of Malignancies
Malignancies are unquestionably a significant public health problem. Their effective treatment is still a big challenge for modern medicine. Tumors have developed a wide range of mechanisms to evade an immune and therapeutic response. As a result, there is an unmet clinical need for research on solutions aimed at overcoming this problem. An accumulation of tryptophan metabolites belonging to the kynurenine pathway can enhance neoplastic progression because it causes the suppression of immune system response against cancer cells. They are also involved in the development of the mechanisms responsible for the resistance to antitumor therapy. Kynurenine belongs to the most potent immunosuppressive metabolites of this pathway and has a significant impact on the development of malignancies. This fact prompted researchers to assess whether targeting the enzymes responsible for its synthesis could be an effective therapeutic strategy for various cancers. To date, numerous studies, both preclinical and clinical, have been conducted on this topic, especially regarding the inhibition of indoleamine 2,3-dioxygenase activity and their results can be considered noteworthy. This review gathers and systematizes the knowledge about the role of the kynurenine pathway in neoplastic progression and the findings regarding the usefulness of modulating its activity in anticancer therapy.
- 23 June 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 606
Open AccessKynurenines as a Novel Target for the Treatment of Malignancies
Malignancies are unquestionably a significant public health problem. Their effective treatment is still a big challenge for modern medicine. Tumors have developed a wide range of mechanisms to evade an immune and therapeutic response. As a result, there is an unmet clinical need for research on solutions aimed at overcoming this problem. An accumulation of tryptophan metabolites belonging to the kynurenine pathway can enhance neoplastic progression because it causes the suppression of immune system response against cancer cells. They are also involved in the development of the mechanisms responsible for the resistance to antitumor therapy. Kynurenine belongs to the most potent immunosuppressive metabolites of this pathway and has a significant impact on the development of malignancies. This fact prompted researchers to assess whether targeting the enzymes responsible for its synthesis could be an effective therapeutic strategy for various cancers. To date, numerous studies, both preclinical and clinical, have been conducted on this topic, especially regarding the inhibition of indoleamine 2,3-dioxygenase activity and their results can be considered noteworthy. This review gathers and systematizes the knowledge about the role of the kynurenine pathway in neoplastic progression and the findings regarding the usefulness of modulating its activity in anticancer therapy.
- Open Access
- 19 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 5979
Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401
An increase in the peripheral synthesis of serotonin and kynurenine, observed during the chronic kidney disease (CKD) course, is negatively associated with bone health. Serotonin and kynurenine are connected by the common precursor, tryptophan. LP533401 is an inhibitor of peripheral serotonin synthesis. This study aimed to establish if the inhibition of serotonin synthesis by LP533401 may affect the kynurenine pathway activity in bone tissue and its potential consequence with regard to osteogenesis and bone mineral status. Nephrectomized rats were treated with LP533401 at a dose of 30 and 100 mg/kg daily for eight weeks. Tryptophan and kynurenine concentrations were determined, and tryptophan 2,3-dioxygenase (TDO) expression was assessed. We discovered the presence of a TDO-dependent, paracrine kynurenic system in the bone of rats with CKD. Its modulation during LP533401 treatment was associated with impaired bone mineral status. Changes in TDO expression affecting the kynurenine pathway activity were related to the imbalance between peripheral serotonin and 25-hydroxyvitamin D. There were also close associations between the expression of genes participating in osteoblastogenesis and activation of the kynurenine pathway in the bones of LP53301-treated rats. Our results represent the next step in studying the role of tryptophan metabolites in renal osteodystrophy.
- 19 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 5979
Open AccessModulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401
An increase in the peripheral synthesis of serotonin and kynurenine, observed during the chronic kidney disease (CKD) course, is negatively associated with bone health. Serotonin and kynurenine are connected by the common precursor, tryptophan. LP533401 is an inhibitor of peripheral serotonin synthesis. This study aimed to establish if the inhibition of serotonin synthesis by LP533401 may affect the kynurenine pathway activity in bone tissue and its potential consequence with regard to osteogenesis and bone mineral status. Nephrectomized rats were treated with LP533401 at a dose of 30 and 100 mg/kg daily for eight weeks. Tryptophan and kynurenine concentrations were determined, and tryptophan 2,3-dioxygenase (TDO) expression was assessed. We discovered the presence of a TDO-dependent, paracrine kynurenic system in the bone of rats with CKD. Its modulation during LP533401 treatment was associated with impaired bone mineral status. Changes in TDO expression affecting the kynurenine pathway activity were related to the imbalance between peripheral serotonin and 25-hydroxyvitamin D. There were also close associations between the expression of genes participating in osteoblastogenesis and activation of the kynurenine pathway in the bones of LP53301-treated rats. Our results represent the next step in studying the role of tryptophan metabolites in renal osteodystrophy.
- 1 June 2020
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (Supplement)
P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY
Background and Aims: Abnormalities in bone metabolism represent the most complex disorder accompanying a chronic kidney disease (CKD) development. Serotonin – one of the tryptophan metabolites, has received intensive attention due to its potential role in bone metabolism. The synthesis of peripheral serotonin is initiated by the tryptophan hydroxylase-1 (TPH-1) in the gut. LP533401 is a small-molecule inhibitor of TPH-1. Previously, we found that inhibition of TPH-1 by LP533401 may improve bone mineralization in rats with experimentally induced CKD (Pawlak et al, Bone, 2018). The aim of this study was to establish whether the inhibition of serotonin synthesis by LP533401 may affect kynurenine pathway activity in bone tissue of nephrectomized rats, and to determine the potential consequence of this process in relation to osteoblastogenesis. Method: Nephrectomized rats were randomized into: untreated (CKD), treated with vehicle (VEH), treated with LP533401 at a dose of 30 (LP 30) and 100 mg/kg (LP 100) daily for 8 weeks. The shame-operated animals served as controls (CON). Tryptophan (TRP) and kynurenine (KYN) concentrations in trabecular and cortical homogenates of femoral bone were determined using high-performance liquid chromatography (HPLC). The expression of tryptophan 2,3-dioxygenase (TDO) as well as genes associated with osteoblastogenesis: activating transcription factor 4 (ATF4), forkhead box protein O1 (FOXO1), Cyclin D1, osteocalcin (Bglap) and sclerostin (Sost) were assessed using the QRT-PCR method. Results: We demonstrated a presence of TDO-dependent, paracrine kynurenic system in bone homogenates of rats with CKD. The significant decrease in TDO mRNA level was observed in the bone of all nephrectomized groups in comparison with CON (all p<0.0001). In LP 100 group, the TDO expression was still lower than in CON, but was significantly higher than in VEH and LP 30-treated groups (both p<0.0001). TDO expression was positively associated with KYN concentration and KYN/TRP ratio (R = 0.426, p = 0.016 and R = 0.559, p = 0.001; respectively) in trabecular bone region. ATF4 gene expression in bone was similar in LP 30 and CON, whereas it was significantly higher in other studied groups compared to healthy animals, and the positive relationship existed between ATF4 and TDO expression (R = 0.372, p = 0.042) as well as between ATF4 gene expression and KYN/TRP ratio both in trabecular and cortical bone tissue (R = 0.485, p = 0.006 and R = 0.421, p = 0.023; respectively) of LP-treated rats. In contrast, cyclin D1 mRNA level was the lowest in LP 100 group compared to other studied groups, and the inverse relationship was between this gene and TDO expression (R = -0.622, p = 0.0002). Bglap mRNA level was higher in CKD and VEH group compared to CON (p<0.05 and p<0.0001; respectively). CKD rats treated with LP 30 had the lowest Bglap mRNA levels among all analyzed uremic groups (all p<0.0001), and the positive relationship was between this gene expression and both TDO expression and KYN/TRP ratio (R = 0.468, p = 0.011 and R = 0.474, p = 0.008; respectively) in trabecular bone of uremic rats treated with LP. Similarly, Sost gene expression was significantly reduced in LP 30 group in comparison with other studied groups (all p<0.0001), and it was positively correlated with TDO expression and KYN/TRP ratio (R = 0.540, p = 0.002 and R = 0.409, p = 0.022; respectively) in trabecular bone tissue. Conclusion: This study for the first time demonstrated the presence of a TDO-dependent, paracrine kynurenic system in the bone of rats with CKD. The modulation of this system during LP533401 treatment was closely associated with the expression of genes participating in osteoblastogenesis, particularly with osteoblast maturation markers. These results represent the next step in studying the role of tryptophan metabolites in renal osteodystrophy.
- 1 June 2020
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (Supplement)
P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY
Background and Aims: Abnormalities in bone metabolism represent the most complex disorder accompanying a chronic kidney disease (CKD) development. Serotonin – one of the tryptophan metabolites, has received intensive attention due to its potential role in bone metabolism. The synthesis of peripheral serotonin is initiated by the tryptophan hydroxylase-1 (TPH-1) in the gut. LP533401 is a small-molecule inhibitor of TPH-1. Previously, we found that inhibition of TPH-1 by LP533401 may improve bone mineralization in rats with experimentally induced CKD (Pawlak et al, Bone, 2018). The aim of this study was to establish whether the inhibition of serotonin synthesis by LP533401 may affect kynurenine pathway activity in bone tissue of nephrectomized rats, and to determine the potential consequence of this process in relation to osteoblastogenesis. Method: Nephrectomized rats were randomized into: untreated (CKD), treated with vehicle (VEH), treated with LP533401 at a dose of 30 (LP 30) and 100 mg/kg (LP 100) daily for 8 weeks. The shame-operated animals served as controls (CON). Tryptophan (TRP) and kynurenine (KYN) concentrations in trabecular and cortical homogenates of femoral bone were determined using high-performance liquid chromatography (HPLC). The expression of tryptophan 2,3-dioxygenase (TDO) as well as genes associated with osteoblastogenesis: activating transcription factor 4 (ATF4), forkhead box protein O1 (FOXO1), Cyclin D1, osteocalcin (Bglap) and sclerostin (Sost) were assessed using the QRT-PCR method. Results: We demonstrated a presence of TDO-dependent, paracrine kynurenic system in bone homogenates of rats with CKD. The significant decrease in TDO mRNA level was observed in the bone of all nephrectomized groups in comparison with CON (all p<0.0001). In LP 100 group, the TDO expression was still lower than in CON, but was significantly higher than in VEH and LP 30-treated groups (both p<0.0001). TDO expression was positively associated with KYN concentration and KYN/TRP ratio (R = 0.426, p = 0.016 and R = 0.559, p = 0.001; respectively) in trabecular bone region. ATF4 gene expression in bone was similar in LP 30 and CON, whereas it was significantly higher in other studied groups compared to healthy animals, and the positive relationship existed between ATF4 and TDO expression (R = 0.372, p = 0.042) as well as between ATF4 gene expression and KYN/TRP ratio both in trabecular and cortical bone tissue (R = 0.485, p = 0.006 and R = 0.421, p = 0.023; respectively) of LP-treated rats. In contrast, cyclin D1 mRNA level was the lowest in LP 100 group compared to other studied groups, and the inverse relationship was between this gene and TDO expression (R = -0.622, p = 0.0002). Bglap mRNA level was higher in CKD and VEH group compared to CON (p<0.05 and p<0.0001; respectively). CKD rats treated with LP 30 had the lowest Bglap mRNA levels among all analyzed uremic groups (all p<0.0001), and the positive relationship was between this gene expression and both TDO expression and KYN/TRP ratio (R = 0.468, p = 0.011 and R = 0.474, p = 0.008; respectively) in trabecular bone of uremic rats treated with LP. Similarly, Sost gene expression was significantly reduced in LP 30 group in comparison with other studied groups (all p<0.0001), and it was positively correlated with TDO expression and KYN/TRP ratio (R = 0.540, p = 0.002 and R = 0.409, p = 0.022; respectively) in trabecular bone tissue. Conclusion: This study for the first time demonstrated the presence of a TDO-dependent, paracrine kynurenic system in the bone of rats with CKD. The modulation of this system during LP533401 treatment was closely associated with the expression of genes participating in osteoblastogenesis, particularly with osteoblast maturation markers. These results represent the next step in studying the role of tryptophan metabolites in renal osteodystrophy.
- Open Access
- 1 January 2020
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 13
Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next?
Impaired kidney function and increased inflammatory process occurring in the course of Chronic Kidney Disease (CKD) contribute to the development of complex amino-acid alterations. The essential amino-acid tryptophan (TRP) undergoes extensive metabolism along several pathways, resulting in the production of many biologically active compounds. The results of many studies have shown that its metabolism via the kynurenine pathway is potently increased in the course of CKD. Metabolites of this pathway exhibit differential, sometimes opposite, roles in several biological processes. Their accumulation in the course of CKD may induce oxidative cell damage which stimulates inflammatory processes. They can also modulate the activity of numerous cellular signaling pathways through activation of the aryl hydrocarbon receptor, leading to the disruption of homeostasis of various organs. As a result, they can contribute to the development of the systemic disorders accompanying the course of chronic renal failure. This review gathers and systematizes reports concerning the knowledge connecting the kynurenine pathway metabolites to systemic disorders accompanying the development of CKD.
- 1 January 2020
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 13
Open AccessKynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next?
Impaired kidney function and increased inflammatory process occurring in the course of Chronic Kidney Disease (CKD) contribute to the development of complex amino-acid alterations. The essential amino-acid tryptophan (TRP) undergoes extensive metabolism along several pathways, resulting in the production of many biologically active compounds. The results of many studies have shown that its metabolism via the kynurenine pathway is potently increased in the course of CKD. Metabolites of this pathway exhibit differential, sometimes opposite, roles in several biological processes. Their accumulation in the course of CKD may induce oxidative cell damage which stimulates inflammatory processes. They can also modulate the activity of numerous cellular signaling pathways through activation of the aryl hydrocarbon receptor, leading to the disruption of homeostasis of various organs. As a result, they can contribute to the development of the systemic disorders accompanying the course of chronic renal failure. This review gathers and systematizes reports concerning the knowledge connecting the kynurenine pathway metabolites to systemic disorders accompanying the development of CKD.
- Open Access
- 14 November 2019
- Published by Walter de Gruyter GmbH in Postępy Higieny I Medycyny Doświadczalnej
- Vol. 73, 608-625
Differentiating dysplasia markers in Barrette sophagus and adenocarcinoma
Barrett’s esophagus (BE) is the only known precursor of esophageal adenocarcinoma (EAC). This precancerous lesion can transform into low-grade and high-grade dysplasia, which may develop in the EAC. Therefore, the issues of dysplasia detection and monitoring and early diagnostics for the presence of EAC foci are extremely important factors in the surveillance of patients with BE progression. Histopathological examinations are regarded as the gold standard in the BE progression evaluation. They posses a large clinical utility in the identification of dysplasia and cancer risk stratification in patients with the BE. However, this method is a very subjective, and is heavily dependent on the knowledge and experience of the person conducting it. Therefore, it seems to be important to implement in the BE progression diagnostics sensitive and specific biomarkers that could be used as complementary tests. They could improve detection, stratification and monitoring of the progression of BE and the detection of the EAC early stages. Literature data concerning markers distinguishing between different stages of Barrett’s-related dysplasia and cancer is very scarce. In this article there we collected and characterized the most important data. Apart from this, there is a fairly large group of proteins and genes. Their expression levels allow for the detection of changes during the development of the BE progression. No studies have been carried out yet for their usefulness in differentiating between types of BE-related dysplasia and EAC, but we know that some of them could be useful as auxiliary markers differentiating between different stages of dysplasia and EAC. The article discusses those with the greatest potential.
- 14 November 2019
- Published by Walter de Gruyter GmbH in Postępy Higieny I Medycyny Doświadczalnej
- Vol. 73, 608-625
Open AccessDifferentiating dysplasia markers in Barrette sophagus and adenocarcinoma
Barrett’s esophagus (BE) is the only known precursor of esophageal adenocarcinoma (EAC). This precancerous lesion can transform into low-grade and high-grade dysplasia, which may develop in the EAC. Therefore, the issues of dysplasia detection and monitoring and early diagnostics for the presence of EAC foci are extremely important factors in the surveillance of patients with BE progression. Histopathological examinations are regarded as the gold standard in the BE progression evaluation. They posses a large clinical utility in the identification of dysplasia and cancer risk stratification in patients with the BE. However, this method is a very subjective, and is heavily dependent on the knowledge and experience of the person conducting it. Therefore, it seems to be important to implement in the BE progression diagnostics sensitive and specific biomarkers that could be used as complementary tests. They could improve detection, stratification and monitoring of the progression of BE and the detection of the EAC early stages. Literature data concerning markers distinguishing between different stages of Barrett’s-related dysplasia and cancer is very scarce. In this article there we collected and characterized the most important data. Apart from this, there is a fairly large group of proteins and genes. Their expression levels allow for the detection of changes during the development of the BE progression. No studies have been carried out yet for their usefulness in differentiating between types of BE-related dysplasia and EAC, but we know that some of them could be useful as auxiliary markers differentiating between different stages of dysplasia and EAC. The article discusses those with the greatest potential.
- Open Access
- 1 June 2019
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 34 (Supplement)
FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE
INTRODUCTION: Changes in mineral and bone metabolism belong to the most common disorders associated with the progression of chronic kidney disease (CKD). Our previous studies suggest that elevated levels of peripherally synthesized serotonin and kynurenine may lead to pathological changes of bone structure in an experimental model of CKD (Kalaska et al., Front. Physiol., 2017; Pawlak et al., Bone, 2018). The serotonin and kynurenine pathways are connected by their common precursor, tryptophan. LP533401 is an orally bioavailable small molecule that inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of peripheral serotonin. Its effect on the kynurenine pathway activity remains unexplained. The ultimate aim of the study was to evaluate the effect of LP533401 on tryptophan and kynurenine concentrations in bone tissue in an experimental model of CKD.
- 1 June 2019
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 34 (Supplement)
Open AccessFP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE
INTRODUCTION: Changes in mineral and bone metabolism belong to the most common disorders associated with the progression of chronic kidney disease (CKD). Our previous studies suggest that elevated levels of peripherally synthesized serotonin and kynurenine may lead to pathological changes of bone structure in an experimental model of CKD (Kalaska et al., Front. Physiol., 2017; Pawlak et al., Bone, 2018). The serotonin and kynurenine pathways are connected by their common precursor, tryptophan. LP533401 is an orally bioavailable small molecule that inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of peripheral serotonin. Its effect on the kynurenine pathway activity remains unexplained. The ultimate aim of the study was to evaluate the effect of LP533401 on tryptophan and kynurenine concentrations in bone tissue in an experimental model of CKD.
- Open Access
- 7 January 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (3) , 491-502
The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
Indoxyl sulfate (IS) is one of the most potent uremic toxins involved in chronic kidney disease (CKD) progression, induction of inflammation, oxidative stress, and cardiovascular diseases occurrence. It is proved that hypertension is a common CVD complication and a major death risk factor as well as contributes for decline in a renal function. The aim of our study was to investigate how implementing of antihypertensive therapy impact IS concentrations and the associations between IS and markers of renal function, inflammation and oxidative stress.
- 7 January 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (3) , 491-502
Open AccessThe impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
Indoxyl sulfate (IS) is one of the most potent uremic toxins involved in chronic kidney disease (CKD) progression, induction of inflammation, oxidative stress, and cardiovascular diseases occurrence. It is proved that hypertension is a common CVD complication and a major death risk factor as well as contributes for decline in a renal function. The aim of our study was to investigate how implementing of antihypertensive therapy impact IS concentrations and the associations between IS and markers of renal function, inflammation and oxidative stress.